Endoscopic and bronchoscopic robotics in China spans three mature technology categories and one emerging one. Capsule endoscopy, pioneered in China by Ankon Technologies (OMOM, NaviCam series), is among the most globally successful Chinese medical robot exports, with tens of millions of procedures performed across domestic and international markets. Magnetic-controlled capsule systems extended the category into active stomach and colon imaging, with NaviCam SB/MCE/ProScan addressing different GI segments. Flexible endoscopic platforms — Agilis, Unicorn, Picasso, Duidao UniPath for bronchoscopy — bring motorized insertion, tip articulation, and image processing into procedures that previously relied on manual skill.
Robotic bronchoscopy navigation — a distinct category addressing peripheral pulmonary lesion biopsy and ablation — is advancing through domestic systems (LungPoint, Archimedes LungPro, Infinity, Edge Bronchoscope) and international platforms cleared for China use (Ion Bronchoscopy). These systems target the diagnostic yield problem in lung nodule workup, where conventional bronchoscopy reaches fewer than half of peripheral nodules effectively.
Regulatory pathway here splits sharply: diagnostic capsule and flexible endoscopy carry Class II or III depending on electrosurgical/therapeutic functions; bronchoscopy navigation robots are generally Class III with accompanying software-as-medical-device classification. The 2024–2026 pipeline suggests continued domestic innovation in peripheral pulmonary robotics, where addressable market and clinical need are both substantial.
See data methodology for how this listing is maintained.